Despite the existence of multimodal therapy paradigm, high-grade gliomas (HGGs) remain devastating tumors associated with one of the worst prognoses. Glioblastoma (GBM) is the most frequent reported histologic type with a median survival, after surgery and combined treatment with chemotherapy and radiotherapy, ranging from 12 to 16 months. The poor prognosis is due to the lack of therapeutic efficacy of chemical agents and irradiation in hypoxic tumor areas. Experimental studies have investigated several molecules with the aim to counteract several downstream signaling important in tumor progression, unfortunately without conclusive results.Several studies have shown that the extent of resection improves survival in patients with HGG, although the quest to achieve optimal oncologic outcomes must be tempered with the neurologic result after radical resection.
|Numero di pagine||3|
|Stato di pubblicazione||Published - 2020|
All Science Journal Classification (ASJC) codes
- Clinical Neurology